德谷门冬双胰岛素联合利拉鲁肽在血糖控制不佳的2型糖尿病患者中的应用
Application of insulin degludec/insulin aspart injection combined with liraglutide in patients with type 2 diabetes mellitus with poor glycemic control
崔晓飞 1金杨红1
作者信息
- 1. 濮阳油田总医院药学部,河南 濮阳 457001
- 折叠
摘要
目的:探讨德谷门冬双胰岛素联合利拉鲁肽在血糖控制不佳的 2 型糖尿病患者中的应用.方法:选取 2022年 6 月至 2023 年 6 月间我院收治的血糖控制不佳的 2 型糖尿病患者 92 例,随机分为对照组和观察组(n=46),分别给予德谷门冬双胰岛素或德谷门冬双胰岛素联合利拉鲁肽治疗.治疗 4 w后采用全自动生化分析仪检测患者的餐后 2 h血糖(2-hour post-load-glucose,2hPG)、空腹血糖(Fasting blood glucose,FPG)以及空腹胰岛素水平;使用全自动糖化血红蛋白分析仪检测患者的糖化血红蛋白(Hemoglobin A1c,HbA1c)水平.结果:治疗后,两组的FPG、2hPG以及HbA1c水平均显著降低,且观察组显著低于对照组(P＜0.05).观察组的血糖达标平均时间显著短于对照组(P＜0.05).治疗后,两组的HOMA-β水平均显著升高,HOMA-IR水平均显著降低,且观察组的变化幅度均显著高于对照组(P＜0.05).两组的总不良反应发生率无明显差异(P＞0.05).结论:德谷门冬双胰岛素联合利拉鲁肽能快速降低 2 型糖尿病患者的血糖水平,改善患者的胰岛素功能,且不增加低血糖发生率,安全性较高.
Abstract
Objective:To investigate the application of insulin degludec/insulin aspart injection combined with liraglutide in patients with type 2 diabetes mellitus with poor blood glucose control.Methods:Ninety-two patients with type 2 diabetes mellitus with poor blood glucose control in our hospital from June 2022 to June 2023 were selected and randomly divided into the control group and the observation group(n=46).They were treated with insulin degludec/insulin aspart injection or insulin degludec/insulin aspart injection combined with liraglutide,respectively.After 4 weeks of treatment,the levels of 2-hour post-load-glucose(2hPG),fasting blood glucose(FPG),and fasting insulin were detected by an automatic biochemical analyzer.The level of hemoglobin A1c(HbA1c)was detected by an automatic glycosylated hemoglobin analyzer.Results:After treatment,the levels of FPG,2hPG,and HbA1c in the two groups were significantly decreased,and the observation group was significantly lower than the control group(P<0.05).The average time of blood glucose reaching the standard in the observation group was significantly shorter than in the control group(P<0.05).After treatment,HOMA-β levels of the two groups were significantly increased and the levels of HOMA-IR decreased(P<0.05).Also,the changes in the observation group were significantly higher than those in the control group(P<0.05).However,there is no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).Conclusion:Insulin degludec/insulin aspart injection combined with liraglutide can rapidly reduce the blood sugar level of patients with type 2 diabetes,improve the insulin function of patients,and do not increase the incidence of hypoglycemia,with high safety.
关键词
2型糖尿病/血糖控制不佳/德谷门冬双胰岛素/利拉鲁肽Key words
Type 2 diabetes mellitus/Poor blood glucose control/Insulin degludec/insulin aspart injection/Liraglutide引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据